Dysfunction of intestinal stem cells (ISCs) is a hallmark of IBD, and reducing Enterococcus/tyramine‐mediated suppression of ISCs alleviates colitis.[28] ISCs are a promising therapeutic target for IBD.[29] In mice with colitis, ISCs (Lgr5+ cells) in the intestinal mucosa were significantly reduced compared with normal controls; however, their levels were significantly upregulated following treatment with Bf‐OMVs and miR‐5119 (Figure 9h,i). The gene discussed is LGR5; the disease is inflammatory bowel disease.